Price Don’t Lie: Ultragenyx Pharmaceutical Inc’s Trend Down, Especially After Today’s Weak Session

Price Don't Lie: Ultragenyx Pharmaceutical Inc's Trend Down, Especially After Today's Weak Session

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! About 355,348 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 19.50% since March 9, 2016 and is uptrending. It has outperformed by 12.09% the S&P500.
The move comes after 9 months negative chart setup for the $2.48 billion company. It was reported on Oct, 12 by Barchart.com. We have $62.23 PT which if reached, will make NASDAQ:RARE worth $124.00 million less.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on November, 14. They expect $-1.58 earnings per share, down 53.40% or $0.55 from last year’s $-1.03 per share. After $-1.46 actual earnings per share reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 8.22% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 12 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ultragenyx Pharmaceutical Inc has been the topic of 20 analyst reports since July 27, 2015 according to StockzIntelligence Inc. As per Monday, July 27, the company rating was downgraded by Morgan Stanley. The firm has “Outperform” rating given on Thursday, January 21 by Credit Suisse. Jefferies initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Friday, October 23. Jefferies has “Buy” rating and $108 price target. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has “Outperform” rating given on Friday, February 19 by Leerink Swann. Zacks downgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Tuesday, August 18 to “Buy” rating. SunTrust maintained it with “Buy” rating and $119 target price in Monday, July 13 report. Wedbush maintained Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Tuesday, May 10. Wedbush has “Outperform” rating and $92 price target. On Thursday, September 3 the stock rating was initiated by Citigroup with “Sell”. Stifel Nicolaus initiated it with “Buy” rating and $125 target price in Tuesday, December 1 report. The company was initiated on Tuesday, June 28 by Bank of America.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment decreased to 0.97 in Q2 2016. Its down 0.12, from 1.09 in 2016Q1. The ratio fall, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Highland Capital Mgmt Limited Partnership holds 91,500 shares or 0.19% of its portfolio. The Japan-based Diam Limited has invested 0% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Tortoise Management Limited Company owns 1,095 shares or 0.02% of their US portfolio. Columbia Wanger Asset Ltd Limited Liability Company last reported 863,392 shares in the company. Citigroup Inc has 8,935 shares for 0% of their US portfolio. Creative Planning accumulated 0% or 4,200 shares. Guggenheim Capital Lc holds 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 58,774 shares. Moreover, Clarivest Asset Management Ltd Liability Corp has 0.02% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 12,552 shares. Tocqueville Asset Mgmt Limited Partnership, a New York-based fund reported 16,700 shares. Tiaa Cref Investment Mngmt accumulated 152,665 shares or 0.01% of the stock. Gilder Gagnon Howe And Communications Ltd Limited Liability Company has 0.01% invested in the company for 6,842 shares. Goldman Sachs Grp Incorporated has 0.01% invested in the company for 636,433 shares. The France-based Axa has invested 0.05% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Blackrock Gp has 22,930 shares for 0% of their US portfolio. Polar Capital Llp has 0% invested in the company for 4,917 shares.

Another recent and important Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) news was published by Investorplace.com which published an article titled: “3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx …” on July 14, 2016.

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment